{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:26:49Z","timestamp":1755034009336},"reference-count":95,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.eimc.2011.07.003","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T20:47:04Z","timestamp":1318279624000},"page":"691-701","source":"Crossref","is-referenced-by-count":9,"title":["Infecci\u00f3n por virus de la inmunodeficiencia humana y hepatitis v\u00edricas"],"prefix":"10.1016","volume":"29","author":[{"given":"Vicente","family":"Soriano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Martin-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Labarga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2011.07.003_bib0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with HIV infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0010","first-page":"27","article-title":"Hepatitis B virus co-infection in HIV-infected subjects","volume":"4","author":"Puoti","year":"2002","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2011.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1086\/379774","article-title":"Treatment of chronic hepatitis B in the HIV-infected patient: present and future","volume":"37","author":"N\u00fa\u00f1ez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"Frequent hepatitis B virus rebound among HIV-HBV coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200528010-00004","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"28","author":"N\u00fa\u00f1ez","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.eimc.2011.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0040","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-200210180-00024","article-title":"Lack of \u0301occult\u0301 hepatitis B virus infection in HIV-infected patients","volume":"16","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0045","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","article-title":"Evaluation of chronic hepatitis B virus (HBV) infection in co-infected patients receiving lamivudine as component of anti-HIV regimen","volume":"32","author":"Hoff","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.510300525","article-title":"Long term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00002030-200006160-00007","article-title":"Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR coordinating committee","volume":"14","author":"Pillay","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy naive and experienced patients coinfected with HIV-1 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/jhep.2002.35328","article-title":"Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication","volume":"36","author":"Van B\u00f6mmel","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0070","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1097\/00002030-200211220-00023","article-title":"Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine","volume":"16","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0075","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/345770","article-title":"Tenofovir disoproxil fumarate therapy for chronic hepatitis B in HIV\/hepatitis B virus-coinfected individuals for whom interferon and lamivudine therapy have failed","volume":"186","author":"Ristig","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0080","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200301093480218","article-title":"Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus","volume":"348","author":"Benhamou","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0095","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/01.aids.0000189563.79976.05","article-title":"Risk of selecting K65R in antiretroviral-na\u00efve HIV-infected individuals with chronic hepatitis B treated with adefovir","volume":"19","author":"Sheldon","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(01)05840-8","article-title":"Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study","volume":"358","author":"Benhamou","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0105","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.46.6.1734-1740.2002","article-title":"Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection","volume":"46","author":"Gish","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2011.07.003_bib0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eimc.2011.07.003_bib0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1258\/ijsa.2010.010234","article-title":"European guideline for the management of hepatitis B and C virus infections, 2010","volume":"21","author":"Brook","year":"2010","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0120","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/QAD.0b013e3282f8b46f","article-title":"Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0125","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/08892220152644160","article-title":"Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients","volume":"17","author":"Mart\u00edn-Carbonero","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2011.07.003_bib0130","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons with the HIV: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-realted hepatotoxicity","volume":"52","author":"Nu\u00f1ez","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0145","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/432762","article-title":"Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy","volume":"192","author":"Rockstroh","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/431486","article-title":"Association of unsafe sex and increased incidence of hepatitis C infection in HIV-infected men who have sex with men","volume":"41","author":"Rauch","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0155","first-page":"245","article-title":"Acute hepatitis C in HIV-positive individuals","volume":"10","author":"Low","year":"2008","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2011.07.003_bib0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV-infected individuals: recommendatiosn from the European AIDS RTreatment Network (NEAT) consensus conference","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0165","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: updated recommendations from the HIV-HCV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0170","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","article-title":"Spontaneous viral clearance, viral load, and genotype distribution of HCV in HIV-infected patients with HCV antibodies in Europe","volume":"198","author":"Soriano","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/00002030-199510000-00003","article-title":"High hepatitis C viremia and impaired antibody response in patients coinfected with HIV","volume":"9","author":"Cribier","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1089\/aid.2006.0085","article-title":"Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases","volume":"23","author":"Maida","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2011.07.003_bib0185","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfections","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(00)04482-2","article-title":"HIV-1 progression in hepatitis C-infected drug users","volume":"357","author":"Soriano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.07.003_bib0200","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/aid.2005.21.527","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient\/physician choice in patients with hepatitis C coinfection","volume":"21","author":"Mocroft","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2011.07.003_bib0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00042560-200205010-00008","article-title":"Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy","volume":"30","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1016\/j.eimc.2011.07.003_bib0210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.07.003_bib0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.07.003_bib0220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/viro.1998.9130","article-title":"Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters","volume":"244","author":"Beld","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV-RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2011.07.003_bib0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2249.2008.03797.x","article-title":"Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with HIV and\/or hepatitis C virus","volume":"155","author":"Rall\u00f3n","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eimc.2011.07.003_bib0235","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1086\/318539","article-title":"HCV load is associated with HIV-1 disease progression in hemophiliacs","volume":"183","author":"Daar","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0240","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/317644","article-title":"Liver fibrosis progression is related to CD4+ cell depletion in patients with hepatitis C and HIV coinfection","volume":"183","author":"Puoti","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV","volume":"36","author":"Martinez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C \u2013 a European collaborative study","volume":"38","author":"Martin-Carbonero","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0255","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0260","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2893.2009.01261.x","article-title":"Risk factors fro advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance","volume":"18","author":"Blanco","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.eimc.2011.07.003_bib0270","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated interferon-a2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0275","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0280","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.07.003_bib0285","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0290","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0295","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Res Human Retroviruses"},{"key":"10.1016\/j.eimc.2011.07.003_bib0300","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/135965350400900616","article-title":"Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0305","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/630205","article-title":"Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients","volume":"49","author":"Medrano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0310","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0315","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002;123:2082\u201399.","DOI":"10.1053\/gast.2002.1232082"},{"key":"10.1016\/j.eimc.2011.07.003_bib0320","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"HCV and HIV dynamics during HCV treatment in HIV\/HCV coinfection","volume":"188","author":"Torriani","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0325","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e31802b812d","article-title":"Predictive value of early virologic response in HIV\/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin","volume":"44","author":"Laguno","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2011.07.003_bib0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0b013e3282f1da99","article-title":"Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C","volume":"22","author":"Martin-Carbonero","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0335","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/135965350400900411","article-title":"Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis C\/HIV-infected patients","volume":"128","author":"Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0345","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/135965350501000512","article-title":"Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C","volume":"10","author":"Nunez","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.eimc.2011.07.003_bib0355","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"Soriano","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2011.07.003_bib0360","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2003.12.017","article-title":"Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomised trial in 300 patients","volume":"40","author":"Brouwer","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2011.07.003_bib0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0370","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modeling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2011.07.003_bib0375","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.qai.0000170034.90438.68","article-title":"Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV\/hepatitis C virus-coinfected patients","volume":"39","author":"Rendon","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"10.1016\/j.eimc.2011.07.003_bib0380","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/340199","article-title":"Treatment of hepatitis C and anemia in HIV-infected patients","volume":"185","author":"Dieterich","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0385","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/aid.2009.0120","article-title":"Pre-emptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C","volume":"26","author":"Vispo","year":"2010","journal-title":"AIDS Res Human Retroviruses"},{"issue":"Suppl","key":"10.1016\/j.eimc.2011.07.003_bib0390","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2011.07.003_bib0395","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2011.07.003_bib0400","first-page":"150","article-title":"Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies","volume":"3","author":"Moyle","year":"2001","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2011.07.003_bib0405","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/135965350501000410","article-title":"Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin","volume":"10","author":"De Mendoza","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0410","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrosis during interferon therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.07.003_bib0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAI.0b013e318040b2b6","article-title":"Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?","volume":"45","author":"Bani-Sadr","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2011.07.003_bib0420","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","article-title":"Low response to pegylated interferon plus ribavirin in HIv-infected patients with chronic hepatitis C treated with abacavir","volume":"13","author":"Vispo","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0425","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jac\/dkn420","article-title":"Efficacy of pegylated interferon plsu ribavirin treatment in HIV\/HCV coinfected patients receiving abacavir plus lamivudine or tenofovir plsu either lamivudine or emtricitabine as nucleoaide analogue backbone","volume":"62","author":"Mira","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.07.003_bib0430","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/QAI.0b013e3181bd5ce1","article-title":"Rate and predictors of success in the re-treatment of chronic hepatitis C in HIV\/HCV coinfected patients with prior non-response or relapse","volume":"53","author":"Labarga","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2011.07.003_bib0435","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for HCV infection","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0440","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New directly acting antivirals for hepatitis C: potential for interactions with antiretrovirals","volume":"65","author":"Seden","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.07.003_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkn175","article-title":"Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?","volume":"62","author":"Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2011.07.003_bib0450","unstructured":"Sulkowski M, Dieterich D, Sherman K, Rockstroh J, Adda N, Manke N, et al. Interim analysis of a phase 2a double-blind study of TVR in combination with pegIFN and RBV in HIV\/HCV-coinfected patients. CROI 2011, Boston, MA [abstract 146LB]."},{"issue":"Suppl","key":"10.1016\/j.eimc.2011.07.003_bib0455","first-page":"15","article-title":"HDV: thirty years later","volume":"43","author":"Rizzetto","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.eimc.2011.07.003_bib0460","unstructured":"Soriano V, Grint D, d\u2019Arminio-Monforte A, Horban A, Leen C, Poveda E, et al. Delta hepatitis in HIV-infected individuals in Europe. AIDS. En prensa."},{"key":"10.1016\/j.eimc.2011.07.003_bib0465","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2011.07.003_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350801300110","article-title":"Does treatment of hepatitis B virus infection reduce hepatitis delta virus replication in HIV-HBV-HDV coinfected patients?","volume":"13","author":"Sheldon","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2011.07.003_bib0475","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAD.0b013e328340fde2","article-title":"Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues","volume":"25","author":"Martin-Carbonero","year":"2011","journal-title":"AIDS"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11002163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11002163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T10:11:25Z","timestamp":1686391885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X11002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0213005X11002163"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2011.07.003","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}